Central European Journal of Medicine

, Volume 9, Issue 5, pp 704–708 | Cite as

Serum levels of sFas and sFasL in subjects with type 2 diabetes — the impact of arterial hypertension

  • Nikolay StoynevEmail author
  • Krassimir Kalinov
  • Georgi Kirilov
  • Tsvetalina Tankova
Research Article



To evaluate the serum levels of sFas and sFasL in normotensive subjects with different degree of impairment of glucose tolerance as well as in type 2 diabetic patients with treated and treatment-naïve hypertension (AHT).

Material and methods

124 subjects (63 males and 61 females), of mean age 46,31±10,78 years are included in the study, divided in 5 age-matched groups: 19 subjects with type 2 diabetes (DM) and drug-controlled AHT; 30 subjects with type 2 DM and drug-naïve AHT; 30 normotensive subjects with type 2 DM; 26 normotensive subjects with prediabetes and 19 healthy controls. Serum sFas and sFasL levels are determined by highly sensitive enzyme immunoassay technique.


No significant differences in sFas are observed among the studied groups. The levels of sFasL are decreased in normotensive subjects with type 2 DM (p<0,05), while subjects with prediabetes have intermediate values. In both hypertensive groups with DM sFasL levels are further decreased.


Serum sFas levels probably are not associated with the presence of impairment of glucose tolerance or AHT. Serum sFasL values tend to be decreased in subjects with impairment in glucose tolerance; further decrease is observed in hypertensive subjects with type 2 DM. Antihypertensive treatment does not influence the levels of sFasL.


sFas sFasL Hemodialysis Diabetes Prediabetes Hypertension 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. [1]
    Nelson RG, Knowler RG, Petit DJ, Bennett PH. Kidney disease in diabetes. Diabetes in America. 2nd edn. Bethesda, MD: National Institutes of Health; 1995. Report No.95-1468. pp349–400Google Scholar
  2. [2]
    Rachmani R, Ravid M Risk factors for nephropathy in type 2 diabetes mellitus. Compr Ther. 1999 Jun–Jul;25(6–7):366–369PubMedCrossRefGoogle Scholar
  3. [3]
    Rydén L, Standl E, Bartnik M, Van den Berghe G, Betteridge J, de Boer MJ, et al.: The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD). Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary. Eur Heart J. 2007 Jan;28(1):88–136PubMedGoogle Scholar
  4. [4]
    Bennett MR Apoptosis in the cardiovascular system. Heart 2002; 87(5): 480–487PubMedCentralPubMedCrossRefGoogle Scholar
  5. [5]
    Cosson E, Brinquier AF, Paries J, Guillot R, Vaysse J, Attali JR, et al. Fas/Fas-Ligand pathway is impaired in patients with type 2 diabetes. Influence of hypertension and insulin resistance. Diabetes Metab 2005; 31(1): 47–54Google Scholar
  6. [6]
    Midis GP, Shen Y, Owen-Schaub LB Elevated soluble Fas (sFas) levels in nonhematopoietic human malignancy. Cancer Res. 1996; 56(17):3870–3874PubMedGoogle Scholar
  7. [7]
    Blanco-Colio LM, Martín-Ventura JL, de Teresa E, Farsang C, Gaw A, Gensini G, et al.; ACTFAST investigators. Increased soluble Fas plasma levels in subjects at high cardiovascular risk: Atorvastatin on Inflammatory Markers (AIM) study, a substudy of ACTFAST. Arterioscler Thromb Vasc Biol. 2007 Jan;27(1):168–174. Epub 2006 Oct 19Google Scholar
  8. [8]
    García-Unzueta MT, Pesquera C, Calzada E, De la Mora A, Muñoz P, Llorca J, et al. Blood-soluble Fas levels are increased in type 2 diabetic patients with peripheral vascular disease. Horm Metab Res. 2006 Oct;38(10):673–677PubMedCrossRefGoogle Scholar
  9. [9]
    Masse M, Hébert MJ, Troyanov S, Vigneault N, Sirois I, Madore F. Soluble Fas is a marker of peripheral arterial occlusive disease in haemodialysis patients. Nephrol Dial Transplant. 2002 Mar;17(3):485–491PubMedCrossRefGoogle Scholar
  10. [10]
    Troyanov S, Hébert MJ, Masse M, Vigneault N, Sirois I, Madore F Soluble Fas: a novel predictor of atherosclerosis in dialysis patients. Am J Kidney Dis. 2003 May;41(5):1043–1051PubMedCrossRefGoogle Scholar
  11. [11]
    Hébert MJ, Masse M, Vigneault N, Sirois I, Troyanov S, Madore F. Soluble Fas is a marker of coronary artery disease in patients with end-stage renal disease. Am J Kidney Dis. 2001 Dec;38(6):1271–1276PubMedCrossRefGoogle Scholar
  12. [12]
    Tomiyama C, Higa A, Dalboni MA, Cendoroglo M, Draibe SA, Cuppari L, et al. The impact of traditional and non-traditional risk factors on coronary calcification in pre-dialysis patients. Nephrol Dial Transplant. 2006 Sep;21(9):2464–71. Epub 2006 May 30PubMedCrossRefGoogle Scholar
  13. [13]
    World Health Organization. Definition and diagnosis of diabetes mellitus and intermediate hyperglycemia. Report of a WHO/IDF consultation. Geneva; 2006Google Scholar
  14. [14]
    Mancia G, De Backer G, Dominiczak A, Cifkova R, Fagard R, Germano G, et al.: The Task Force for the Management of Arterial Hypertension of the European Society for Hypertension (ESH) and of the European Society of Cardiology (ESC). 2007 Guidelines for the management of arterial hypertension. Eur Heart J 2007; 28:1462–1536PubMedGoogle Scholar
  15. [15]
    Kumar H, Mishra M, Bajpai S, Pokhria D, Arya AK, Singh RK, et al. Correlation of insulin resistance, beta cell function and insulin sensitivity with serum sFas and sFasL in newly diagnosed type 2 diabetes. Acta Diabetol. 2013 Aug;50(4):511–518PubMedCrossRefGoogle Scholar
  16. [16]
    Mahfouz MH, Emara IA, Omar GA Biomarkers of Oxidative DNA Damage and Soluble Fas/Fas Ligand in Type 2 Diabetic Patients. American Journal of Applied Sciences 2012; 9(4):450–458CrossRefGoogle Scholar
  17. [17]
    Protopsaltis T, Kokkoris S, Nikolopoulos G, Spyropoulou P, Katsaros T, Salvanos L, et al. Correlation between increased serum sFas levels and microalbuminuria in type 1 diabetic patients. Med Princ Pract 2007; 16(3): 222–225PubMedCrossRefGoogle Scholar
  18. [18]
    Guillot R, Brinquier AF, Porokhov B, Guillausseau PJ, Feldmann G Increased levels of soluble Fas in serum from diabetic patients with neuropathy. Diabetes Metab 2001; 27(3): 315–321PubMedGoogle Scholar
  19. [19]
    Niewczas MA, Ficociello LH, Johnson AC, Walker W, Rosolowsky ET, Roshan B, et al. Serum concentrations of markers of TNFalpha and Fas-mediated pathways and renal function in nonproteinuric patients with type 1 diabetes. Clin J Am Soc Nephrol. 2009 Jan;4(1):62–70. Epub 2008 Dec 10PubMedCentralPubMedCrossRefGoogle Scholar
  20. [20]
    Baba K, Minatoguchi S, Sano H, Kagawa T, Murata I, Takemura G, et al. Involvement of apoptosis in patients with diabetic nephropathy: A study on plasma soluble Fas levels and pathological findings. Nephrology (Carlton). 2004 Apr;9(2):94–99CrossRefGoogle Scholar
  21. [21]
    Tankova T. Assessment of overall individual risk of diabetes. Dissertation, 2012Google Scholar
  22. [22]
    Tamakoshi A, Suzuki K, Lin Y, Ito Y, Yagyu K, Kikuchi S, et al.; JACC Study Group. Relationship of sFas with metabolic risk factors and their clusters. Eur J Clin Invest. 2010 Jun;40(6):527–533PubMedCrossRefGoogle Scholar
  23. [23]
    Karthikeyan VJ, Lip GY, Baghdadi S, Lane DA, Beevers DG, Blann AD. Soluble Fas and Fas ligand in pregnancy: influence of hypertension. Angiology. 2012 Jan;63(1):35–38PubMedCrossRefGoogle Scholar
  24. [24]
    Bayram M, Taskaya A, Bagriacik EU, Ilhan MN, Yaman M The effect of maternal serum sFAS/sFASL system on etiopathogenesis of preeclampsia and severe preeclampsia. J Matern Fetal Neonatal Med. 2012 Aug 22. [Epub ahead of print]Google Scholar
  25. [25]
    Okura T, Watanabe S, Jiang Y, Nakamura M, Takata Y, Yang ZH, et al. Soluble Fas ligand and atherosclerosis in hypertensive patients. J Hypertens 2002 May;20(5):895–898PubMedCrossRefGoogle Scholar
  26. [26]
    Cross DS, McCarty CA, Hytopoulos E, Beggs M, Nolan N, Harrington DS, et al. Coronary risk assessment among intermediate risk patients using a clinical and biomarker based algorithm developed and validated in two population cohorts. Curr Med Res Opin. 2012 Nov;28(11):1819–1830PubMedCentralPubMedCrossRefGoogle Scholar

Copyright information

© Versita Warsaw and Springer-Verlag Berlin Heidelberg 2014

Authors and Affiliations

  • Nikolay Stoynev
    • 1
    • 3
    Email author
  • Krassimir Kalinov
    • 2
  • Georgi Kirilov
    • 1
  • Tsvetalina Tankova
    • 1
  1. 1.Clinical Center of EndocrinologyMedical UniversitySofiaBulgaria
  2. 2.New Bulgarian UniversitySofiaBulgaria
  3. 3.Department of PhysiologyMedical UniversitySofiaBulgaria

Personalised recommendations